The only approved entirely human monoclonal antibody Ilaris continuously neutralizes interleukin-1 beta thereby inhibiting inflammation. Novartis division head David Epstein said, "When approved, lIaris will provide a new
Hospitalized sickle cell disease patients experiencing vaso-occlusive crisis were examined for the efficacy, safety and pharmacokinetics of GMI-1070. The double-blinded study enrolled a total of 76 patients between
The approval was based on safety and efficacy data from two double-blind, randomized, multi-center trials conducted in adults whose OAB symptoms were not managed using anticholinergic treatments. Allergan
The study designed to assess the investigational drug AXL1717 in patients with relapsed or progressive malignant astrocytomas (glioblastoma and anaplastic astrocytoma) is conducted at the Rush University Medical
POD that facilitates a cleanroom space of 768ft² in addition to a partial ceiling height of 15′ is designed to preserve relative humidity at 35% in a controlled
The collaboration will focus on developing a system based on Quantum Cascade Laser (QCL) infrared spectroscopy for the noncontact cleaning verification of vessels throughout the manufacturing process. The
The energy supplement that is free from fat contains no related caffeine or sugar thereby avoiding unwanted side effects, according to the company. Essential Edibles founder and CEO
The bosutinib positive CHMP opinion is concerned with the conditional marketing authorization in the European Union for the treatment of different phases of philadelphia chromosome positive chronic myelogenous
Phase 1 trial, being conducted in the US, Canada and Denmark, will assess the most favorable KPT-330 dose to treat advanced hematologic malignancies. Karyopharm founder, chief scientific officer
The technology will be evaluated in refolding difficult to express microbial products that are expressed as inclusion bodies, under the agreement. BaroFold CSO and Founder Matthew Seefeldt said,
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.